Post

1) The pilot results (n = 10) for the Daratumumab trial on ME/CFS have been published and they look quite encouraging. Tolerability and feasibility were good and some patients had substantial improvements.

3) The authors speculate that after an infection, long-lived plasma cells are producing antibodies in ME/CFS. Since these plasma cells are CD20 negative, they are not affected by (short-term) Ritxumab treatment. Hence the idea to try Daratumumab which does target these cells.

4) Four patients had no significant clinical changes, but the improvements in the other patients were quite big. SF-36 physical functioning, for example, increased from 25.9 to 55 (+29), which is bigger than for example GET/CBT in the PACE trial (+18).

5) It's also interesting that improvements are not evenly spread across all participants. Some had no improvement at all, while others were almost back to normal. 5/10 patients had sustained improvement for 12-24 months and had a mean step count above 10,000/24 h for some weeks.